Opinion|Videos|May 27, 2025
Ultra-Low PSA Threshold vs Traditional Thresholds In Clinical Practice
Author(s)Neal Shore, MD, FACS
Exploring the impact of ultra-sensitive PSA testing on treatment decisions for metastatic hormone-sensitive prostate cancer, enhancing patient outcomes and care efficiency.
Advertisement
Episodes in this series
Comparison of PSA Thresholds
Key Themes:
- Comparison between ultra-low threshold (<0.02 ng/mL) and traditional thresholds (<0.1 or <0.2 ng/mL)
- Sensitivity and specificity considerations
- Prognostic value of different PSA cutoff points
Expert Insights:
- Dr Shore discussed the differences between the ultra-low PSA threshold and more conventional thresholds commonly used in clinical practice.
The conversation addressed the sensitivity, specificity, and potential prognostic significance of various PSA cutoff points.
Advertisement
Related to this article
Updated CAPItello-281 data support capivasertib plus abiraterone in PTEN-deficient mHSPC, according to Daniel J. George, MD.
Benjamin Garmezy, MD, discusses personalizing mHSPC treatment intensification based on disease burden, molecular biomarkers, and patient-specific factors.
Biomarkers including HRR mutations, PTEN loss, and PSMA expression can guide triplet selection in mHSPC, according to Benjamin Garmezy, MD.
Alicia Morgans, MD, discusses ARACOG findings on cognitive outcomes with darolutamide vs enzalutamide and the influence of genetic dementia risk.
Aaron Berger, MD, discusses patient selection for ARPI treatment holidays, monitoring during interruptions, and the role of testosterone recovery in interpreting PSA kinetics.
Tamim Niazi, MDCM, reviews DASL-HiCaP findings showing improved metastasis-free survival with darolutamide added to ADT and radiation therapy.
Chad Ritch, MD, discusses differences between PSMA-PET imaging agents and the need for further evidence to guide clinical decision-making.
Chad Ritch, MD, discusses how PSMA-PET informs patient management across different stages of the prostate cancer journey.
Advertisement
Advertisement
Trending on Urology Times
1
PTEN loss: From biomarker to treatment strategy in mHSPC
2
Q&A: Gary Kirsh, MD, on health policy for independent urology
3
Modern BCG outperforms historic benchmarks in high-risk NMIBC
4
Q&A: Suzanne B. Merrill, MD, FACS, on treating high-risk NMIBC
5